Oncolytics Biotech Inc. (NASDAQ:ONCY) shares traded -10.32% lower at $2.52 on Wall Street last session.
In accordance with the data, 7 analysts cover Oncolytics Biotech Inc. (NASDAQ:ONCY). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $4.46, we find $6.37. Given the previous closing price of $2.81, this indicates a potential upside of 126.69 percent. ONCY stock price is now 7.01% away from the 50-day moving average and 46.07% away from the 200-day moving average. The market capitalization of the company currently stands at $157.12M.
It has been rated a hold by 0 analysts and a buy by 7. Brokers who have rated the stock have averaged $7.07 as their price target over the next twelve months.
With the price target of $3, Maxim Group recently initiated with Buy rating for Oncolytics Biotech Inc. (NASDAQ: ONCY).
A total of 1.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ONCY stock. A new stake in Oncolytics Biotech Inc. shares was purchased by BRAVE ASSET MANAGEMENT INC during the first quarter worth $25,000. In total, there are 39 active investors with 2.50% ownership of the company’s stock.
Oncolytics Biotech Inc. (NASDAQ: ONCY) opened at $2.4600 on Monday. During the past 12 months, Oncolytics Biotech Inc. has had a low of $1.09 and a high of $3.39. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 13.90, and a quick ratio of 13.90. The fifty day moving average price for ONCY is $2.3742 and a two-hundred day moving average price translates $1.7316 for the stock.
The latest earnings results from Oncolytics Biotech Inc. (NASDAQ: ONCY) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.08, beating analysts’ expectations of -$0.1 by 0.02. This compares to -$0.09 EPS in the same period last year. The company reported revenue of $4.98 million for the quarter, compared to $4.98 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -0.08 percent.
Oncolytics Biotech Inc.(ONCY) Company Profile
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
